 Kintara Inc, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reports that it closed its fiscal year on June 30 with cash and cash equivalents of about 10.5 million. In a statement, the company noted that its balance sheet as of September 28 grew even stronger as it closed on a registered direct offering, priced at-the-market under Nasdaq rules, raising about 15 million to help fund ongoing clinical studies and corporate working capital needs. 